Serial #87052324
DEAD

Serial Number

87052324

Owner

Crescendo Biologics Limited

Attorney

Mark Harrison

Filing Date

May 27, 2016

Add to watchlist:

No watchlists yet
View on USPTO

Serial #87052324 Trademark

Serial Number: 87052324 • Registration: 5332632

Serial #87052324 is a trademark filed by Crescendo Biologics Limited on May 27, 2016. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 31 (Natural Agricultural Products). The application is currently no longer active.

Owner Contact Info

Crescendo Biologics Limited (6 trademarks)

Meditrina Building,

Entity Type: 99

Trademark Details

Filing Date

May 27, 2016

Registration Date

November 14, 2017

Published for Opposition

August 29, 2017

Cancellation Date

May 28, 2024

Goods & Services

Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments

Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; monoclonal antibody therapeutic preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; antibodies and antibody fragments being diagnostic reagents for medical and veterinary diagnostics; antibodies and antibody fragments for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases for use in the manufacture of therapeutic products

Chemicals for use in industry and science; chemicals test kits for in vitro testing for laboratory research purposes; biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for scientific and laboratory research use; biochemical, namely, monoclonal antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products

Live animals; live mice

Scientific and technological services, namely, scientific research, analysis and testing, and research and design in the field of therapeutic pharmaceuticals; scientific laboratory services; laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, therapeutic products

Filing History

CANCELLED SEC. 8 (6-YR)
May 28, 2024 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Nov 14, 2022 REM1
REGISTERED-PRINCIPAL REGISTER
Nov 14, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 29, 2017 NPUB
PUBLISHED FOR OPPOSITION
Aug 29, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 9, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 26, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 19, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 19, 2017 CRFA
ASSIGNED TO LIE
Jul 18, 2017 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 9, 2017 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Apr 28, 2017 GNS2
INQUIRY TO SUSPENSION E-MAILED
Apr 28, 2017 GNSI
SUSPENSION INQUIRY WRITTEN
Apr 28, 2017 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 28, 2016 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 28, 2016 GNSL
SUSPENSION LETTER WRITTEN
Oct 28, 2016 CNSL
EXAMINER'S AMENDMENT ENTERED
Oct 28, 2016 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 28, 2016 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 28, 2016 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 28, 2016 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 20, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 20, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 20, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 15, 2016 GNRN
NON-FINAL ACTION E-MAILED
Sep 15, 2016 GNRT
NON-FINAL ACTION WRITTEN
Sep 15, 2016 CNRT
ASSIGNED TO EXAMINER
Sep 12, 2016 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 7, 2016 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 4, 2016 NWOS
NEW APPLICATION ENTERED
May 31, 2016 NWAP